nach oben

Current Hypertension Reports

Erschienen in:

01.06.2013 | Hypertension and Obesity (E Reisin, Section Editor)

Obesity and Metabolic Syndrome in Kidney Transplantation

verfasst von: Heather LaGuardia, Rubin Zhang

Erschienen in: Current Hypertension Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The epidemic of obesity and metabolic syndrome (MS) contributes to the rapid growth of chronic kidney disease (CKD) and end-stage renal disease (ESRD). There is a reverse epidemiology, known as the “obesity paradox,” in ESRD patients receiving maintenance dialysis. Obese patients are routinely referred for kidney transplant, and they have more surgical and medical complications than non-obese patients. However, compared to dialysis, kidney transplant provides a survival benefit for obese patients. After kidney transplant, obese patients tend to gain more body weight, and non-obese patients can develop new-onset obesity/MS. Obesity/MS is not only associated with serious morbidities, but also compromises the long-term graft and patient survival. The immunosuppressive drugs commonly used as maintenance therapy, including corticosteroids, calcineurin inhibitors and mammalian target-of-rapamycin inhibitors, contribute to obesity/MS. Development of novel immunosuppressive drugs free of metabolic adverse effects is needed, so that the full potential and benefits of kidney transplantation can be realized.

Zhang R, Lia J, Morse S, et al. Kidney disease in the metabolic syndrome. Am J Med Sci. 2005;330(6):319–25.PubMedCrossRef

Killackey M, Zhang R, Sparks K, et al. Challenges of abdominal organ transplant in obesity. South Med J. 2010;103(6):532–40.PubMedCrossRef

Kambham N, Markowitz G, Valeri A, et al. Obesity related glomeruplopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498–509.PubMedCrossRef

Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–74.PubMedCrossRef

Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134–40.PubMedCrossRef

Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48(3):383–91.PubMedCrossRef

Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278:817–22.

Mathier M, Ramanathan R. Impact of obesity and bariatric surgery on cardiovascular disease. Med Clin N Am. 2007;91:415–31.PubMedCrossRef

Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.PubMedCrossRef

10.

Weinbrenner T, Schroder H, Escurriol V, et al. Circulating oxidized LDL is associated with increased waist circumference independent of body mass index in men and women. Am J Clin Nutr. 2006;83:30–5.PubMed

11.

Bagby S. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15:2775–91.PubMedCrossRef

12.

Wisse B. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:2792–800.PubMedCrossRef

13.

Kimura KA, Sugaya T, et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int. 2002;62:1623–37.

14.

Safardis P, Ruilope L. Insulin resistance, hyperinsulinemia and renal injury: mechanisms and implications. Am J Nephrol. 2006;26:232–44.CrossRef

15.

Alexander MP, Patel TV, Farag YM, et al. Kidney Pathologic changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009;53:751–9.PubMedCrossRef

16.

Ceriello A, Motz E. is oxidative stress the pathologic mechanism underlying insulin resistance, diabetes, and cardiovascular disease: the common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816–23.PubMedCrossRef

17.

Perlstein T, Gerhard-Herman M, Kollemberg N, et al. Insulin induces renal vasodilation, increases plasma rennin acivity and sensitizes the renal vasculature to angiotensin receptor blockage in healthy subjects. J Am Soc Nephrol. 2007;18:944–51.PubMedCrossRef

18.

Morales E, Valero A, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–27.PubMedCrossRef

19.

Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16–23.PubMed

20.

Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–82.PubMed

21.

Fleischmann EH, Bower JD, Salahudeen AK. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J. 2001;47:74–81.PubMedCrossRef

22.

Friedman AN. Adiposity in dialysis: good or bad? Semin Dial. 2006;19:136–40.PubMedCrossRef

23.

Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808.PubMedCrossRef

24.

Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis. 2003;41:925–32.PubMedCrossRef

25.

Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386–94.PubMedCrossRef

26.

Molnar MZ, Streja E, Kovesday CP, et al. Associations of body mass index and weight loss with mortality in transplant waitlisted maintenance of hemodialysis patients. Am J Transplant. 2011;11:725–36.PubMedCrossRef

27.

Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789–95.PubMedCrossRef

28.

Kalantar-Zadeh K, Kopple J. Malnutrition as a cause of morbidity and mortality in dialysis patients. In: Kopple J, Massry S, editors. Nutritional management of renal disease. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2004.

29.

Chung SH, Lindholm B, Lee HB. Is malnutrition an independent predictor of mortality in peritoneal dialysis patients? Nephrol Dial Transplant. 2003;18:2134–40.PubMedCrossRef

30.

Stenvinkel P, Barany P, Heimburger O, et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl. 2002;80:103–8.PubMedCrossRef

31.

Fung F, Sherrard DJ, Gillen DL, et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis. 2002;40:307–14.PubMedCrossRef

32.

Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42:864–81.PubMedCrossRef

33.

Chang S. Effects of body mass index at transplant on outcomes of kidney transplantation. Transplantation. 2007;84:981–7.PubMedCrossRef

34.

Meier-Kriesche H, Arndorfer J, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.PubMedCrossRef

35.

•• Molnar MZ, Kovesdy CP, Musci I, et al. Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int. 2011;80:218–24. The authors analyzed a cohort of 11,836 kidney transplant recipients from the national database of DaVita dialysis patients and the national scientific registry of transplant recipients. They found that pre transplant BMI was independently associated with delayed graft function, which required dialysis support during the first week of kidney transplant surgery.PubMedCrossRef

36.

Marks W, Florence L, Chapman P, et al. Morbid obesity is not a contraindication to kidney transplantation. Am J Surg. 2004;187:635–8.PubMedCrossRef

37.

Massarweh N, Clayton J, Mangum C, et al. High body mass index and short- and long-term renal allograft survival in adults. Transplantation. 2005;80:1430–4.PubMedCrossRef

38.

Yamamoto S, Hanley E, Hahn A, et al. The impact of obesity in renal transplantation: an analysis of paired cadaver kidneys. Clin Transplant. 2002;16:252–6.PubMedCrossRef

39.

Glanton C, Kao T, Cruess D, et al. Impact of renal transplantation on survival in end-stage renal disease with elevated body mass index. Kid Int. 2003;63:647–53.CrossRef

40.

Friedman AN, Miskulin DC, Rosenberg IH, et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41:480–7.PubMedCrossRef

41.

Pelletier S, Maraschio M, Schaubel D, et al. Survival benefit of kidney and liver transplantation for obese patients on the waiting list. Clin Transplant 2003; 77–88.

42.

DeMaria E, Carmody B. Perioperative management of special populations:obesity. Surg Clin N Am. 2005;85:1283–9.PubMedCrossRef

43.

Alexander J, Goodman H. Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract. 2007;22:16–21.PubMedCrossRef

44.

Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The Medical Evaluation of Living Kidney Donors: a survey of US transplant centers. Am J Transplant. 2007;7(10):2333–43.PubMedCrossRef

45.

• Nogueira JM, Weir MR, Jacobs S, et al. A study of renal outcomes in obese living kidney donors. Transplantation. 2010;90(9):993–9. This study looked at the outcomes of obese living donors 6–8 years after kidney donation. They found that those with BMI of >35 kg/m ² were more likely to have significant decrement in renal function as estimated by MDRD-GFR. They also noted a substantial risk of hypertension in obese donors compared to non-obese donors.PubMedCrossRef

46.

Heimbach J, Taler S, Prieto M, et al. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant. 2005;5:1057–64.PubMedCrossRef

47.

Espinoza R. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 2006;38(3):888–9.PubMedCrossRef

48.

Patel S, Cassuto J. Minimizing morbidity of organ donation: analysis of factors for perioperative complications after living-donor nephrectomy in the United States. Transplantation. 2008;85(4):561–5.PubMedCrossRef

49.

Rizvi SA, Naqvi SA, Jawad F, et al. Living kidney donor follow-up in a dedicated clinic. Transplantation. 2005;79:1247–51.PubMedCrossRef

50.

Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360:459–69.PubMedCrossRef

51.

Tavakol MM, Vincenti FG, Assadi H, et al. Long-term renal functionand cardiovascular disease risk in obese kidney donors. Clin J Am Soc Nephrol. 2009;4:1230–8.PubMedCrossRef

52.

• Kovas AZ, Molnar MZ, Szeifert L, et al. Sleep Disorders, depressive symptoms and health related quality of life—a cross sectional comparison between kidney transplant recipients and waitlisted patients on maintenance dialysis. Nephrol Dial Transplant. 2011;26(3):1058–65. This was an observational cross-sectional study of 187 patients from nine dialysis centers examining whether there was any subjective improvement in quality of life between the waitlisted patients on dialysis and those who had received a renal transplant. They found that the patients who received renal transplantation had a significantly better quality of life in respect to sleep, energy, depression and general health perceptions.CrossRef

53.

•• Hoogeveen EK, Aalten J, Rothman KJ, Roodnat JI, et al. Effect of obesity on the outcome of kidney transplantation: a 20 year follow up. Transplantation. 2011;91:869–74. This study compared the effects of pre- and 1-year post-transplant BMI using Cox proportional hazard models. One-year post-transplant BMI was more strongly correlated with patients and graft survival even after adjustment for other cardiovascular risk factors. Those with a BMI > 30 kg/m ² had a 20-40 % higher risk of death and graft failure.PubMedCrossRef

54.

Johnson CP, Gallagher-Lepak S, Zhu YR, et al. Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822–7.PubMedCrossRef

55.

Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69:2227–43.PubMedCrossRef

56.

Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk: a meta-analysis. Transplantation. 2010;89:1–14.PubMedCrossRef

57.

Gaber AO, Moore LW. Patterns of early weight change after renal transplantation. J Ren Nutr. 1996;6:21–5.CrossRef

58.

Demme R. Hypertension in kidney transplant patients. Graft. 2001;4:248–55.CrossRef

59.

Lo A. Immunospuression and metabolic syndrome in renal transplant recipients. Metab Syndr Relat Disord. 2004;2(4):263–73.PubMedCrossRef

60.

Sander M, Lyson T, Thomas GD, Victor RG. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens. 1996;9:121S–38.PubMedCrossRef

61.

Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775–82.PubMedCrossRef

62.

Kobashigawa J, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63:331–8.PubMedCrossRef

63.

Dimeny E, Fellstrom B. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction? Nephrol Dial Transplant. 1997;12:21–4.PubMedCrossRef

64.

Wissing K, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000;70:464–72.PubMedCrossRef

65.

Locsey L, Asztalos L, Kincses Z, et al. The importance of obesity and hyperlipidemia in subjects with renal transplant. Int Urol Nephrol. 1998;30:767–75.PubMedCrossRef

66.

Miller L. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;1:807–18.CrossRef

67.

Kasiske B, Ballantyne CM. Cardiovascular risk factors associated with immunosuppression in renal transplantation. Transplant Rev. 2002;16:1–21.CrossRef

68.

Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor free regimens in cadaveric renal transplantation. Transplantation. 2004;77:1228–35.PubMedCrossRef

69.

Flechner S, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74:1070–8.PubMedCrossRef

70.

Montori VM, Basu A, Erwin PJ, et al. Post transplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583–92.PubMedCrossRef

71.

Ducloux D, Kazory A, Chalopin JM. Post transplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation. 2005;79:438–43.PubMedCrossRef

72.

Kasiske B, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–85.PubMedCrossRef

73.

Pham PT, Danovitch GM, Pham PC. The medical management of the renal transplant recipient. In: Johnson RJ, Feehally J, editors. Comprehensive clinical nephrology. Philadelphia: Mosby; 2007. p. 1085.

74.

Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with post transplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1347–80.CrossRef

75.

Van der Werf N, Kroese FG, Rozing J, et al. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev. 2007;23:169–83.PubMedCrossRef

76.

Hamer RA, Chow CL, Ong AC, et al. Polycystic kidney disease as a risk factor for post transplant diabetes mellitus following renal transplant. Kidney Int. 2005;67:714–20.CrossRef

77.

Reisaeter AV, Hartmann A. Risk factors and incidence of post transplant diabetes mellitus. Transplant Proc. 2001;33(5A suppl):8S.PubMedCrossRef

78.

Esmatjes E, Ricart MJ, Ferrer JP, et al. Cyclosporine’s effect on insulin secretion in patients with kidney transplants. Transplantation. 1991;52:500–3.PubMedCrossRef

79.

Ost L, Tyden G, Fehrman I. Impaired glucose tolerance in cyclosporine prednisolone treated renal graft recipients. Transplantation. 1988;46:370–2.PubMedCrossRef

80.

Nam J, Mun JI, Kim SI, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation. 2001;71:1417–23.PubMedCrossRef

81.

Augustine JA. Use of sirolimus in solid organ transplantation. Drugs. 2007;67:369–291.PubMedCrossRef

82.

Nathaniel B, Cochetti P, Mysore S, et al. Association of metabolic syndrome with development of new-onset diabetes after transplant. Transplantation. 2010;90:861–6.

83.

US Renal Data System, USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010. p. 2010.

84.

Israni A, Snyder J, Skeans M, et al. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int. 2012;25:748–75.PubMedCrossRef

85.

Adeseun GA, Rivera ME, Thota S, et al. Metabolic syndrome and coronary artery calcification in renal transplant recipients. Transplantation. 2008;86:728–32.PubMedCrossRef

86.

Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant. 2004;19:2307–12.PubMedCrossRef

87.

Oschatz E, Benesch T, Kodras K, et al. Changes of coronary calcification after kidney transplantation. Am J Kidney Dis. 2006;48:307–13.PubMedCrossRef

88.

De Vries A, Bakker S, van Son W, et al. Insulin resistance as a putative cause of chronic renal transplant dysfunction. Am J Kidney Dis. 2003;41:859–67.PubMedCrossRef

89.

Ewel C, Foegh M. Chronic graft rejection: accelerated transplant arteriosclerosis. Immunol Rev. 1993;134:21–31.PubMedCrossRef

90.

De Vries A, Bakker S, van Son W, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all components contribute equally. Am J Kidney Dis. 2004;4:1675–83.

91.

Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplant. Am J Kidney Dis. 2006;48:134–42.PubMedCrossRef

92.

• Soveri I, Abedini S, Holadaas H, et al. Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial. J Nephrol. 2012;25(2):245–25. This study challenged the traditional opinion and prior studies regarding metabolic syndrome as an independent risk for graft loss. Here the non-diabetic renal transplant patients enrolled in the ALERT trial were followed for 7–8 years. After adjustment for other known risk factors for renal graft loss, metabolic syndrome was no longer associated with increased risk of graft loss.PubMedCrossRef

93.

•• Larsen CP et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90:1528–35. This study included 493 patients from the BENEFIT and 347 from the BENEFIT-EXT trails. After 2 years, patients on biological co-stimulation blocker belatacept-based therapy had better renal function and similar patient and graft survival compared with those on cyclosporine-based therapy. There were also better metabolic and cardiovascular profiles associated with belatacept compared with cyclosporine therapy.PubMedCrossRef

94.

• Jo P, Grinyo JM, Vanrenterghem Y, et al. Three year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12(3):630–9. This study compared a traditional cyclosporine-based regimen with the new biologic agent beletacept in patients who had received extended criteria donor kidney transplants. They found that the belatecept group had a mean calculated GFR 11 ml/min higher than the cyclosporine treatment group at 3 years and that there was no increased risk of rejection.CrossRef

95.

• Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients. Transplantation. 2011;91(9):976–83. This study analyzed the data from the BENEFIT and BENEFIT-EXT studies specifically looking at cardiacvascular and metabolic endpoints. It was shown that at 12 months, the belatacept regimens were associated with lower blood pressure and lipid levels than the cyclosporine-based therapy. There was a lower incident of new-onset diabetes after transplant (NODAT) in the belatacept group.PubMedCrossRef

Titel: Obesity and Metabolic Syndrome in Kidney Transplantation
verfasst von: Heather LaGuardia
Rubin Zhang
Publikationsdatum: 01.06.2013
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 3/2013
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-013-0335-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Obesity and Metabolic Syndrome in Kidney Transplantation

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Role of Ambulatory Blood Pressure Monitoring in Resistant Hypertension

Treatment of Obesity-Related Hypertension in Children and Adolescents

Ambulatory Blood Pressure Monitoring in the Prediction and Prevention of Coronary Heart Disease

Ambulatory Blood Pressure in Stroke and Cognitive Dysfunction

Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal?

Ambulatory Blood Pressure in Chronic Kidney Disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

Update Innere Medizin